Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Merck & Company, Inc.
WARNING LETTER
•Merck & Company, Inc.•January 17, 2008

Merck & Company, Inc. – FDA Warning Letter, Jan 17, 2008

Record Details

The FDA issued a Warning Letter to Merck and Company, Inc. following an inspection from November 26, 2007, to January 17, 2008, at their West Point, Pennsylvania facility. The inspection revealed significant deviations from Current Good Manufacturing Practice (CGMP) in the manufacture of licensed biological vaccine products, bulk drug substances, and drug components, including Liquid PedvaxHIB?, RECOMBIVAX HB?, ProQuad?, Gardasil?, VAQTA?, and COMVAX?. These violations contravene Section 501(a)(2)(B) of the FD&C Act, requirements of their biologics license application under Section 351 of the PHS Act, and 21 CFR Parts 210 and 211.

Key deficiencies include: - **Inadequate Investigations:** Failure to thoroughly investigate unexplained discrepancies, such as out-of-specification Varivax III, over-pressurization of Zostavax? vials, unassessed product lots affected by shedding fibers, and uninvestigated critical defects in MMR II? lots. - **Complaint Handling:** Inadequate written procedures for handling complaints, specifically regarding lot history for fill lot numbers versus final finish lot numbers. - **Production and Process Controls:** Validation for automated inspection equipment not representative of actual processes, and process control limits for Zostavax? not evaluated as required. - **Equipment Calibration and Maintenance:** Automated inspection

Company
Merck & Company, Inc.
Inspection date
January 17, 2008
Product type
Biologics
Office
Office of Compliance and Enforcement
Person
  • David K. Elder (Principal)
View Company Profile

ID · 93ed085d-29d1-4367-a730-468a32b3b4f9

Violation Codes10
FD&C Act 501(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.19821 CFR 211.100(a)21 CFR 211.68(a)21 CFR 211.68(b)21 CFR 211.160(a)21 CFR 211.160(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Merck & Company, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.